Role of Ivermectin Nanosuspension as Nasal Spray in Treatment of Persistant Post covid19 Anosmia

Last updated: April 14, 2022
Sponsor: South Valley University
Overall Status: Active - Recruiting

Phase

2/3

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT04951362
SVU MED CIT0 23 4 21 1 122
  • Ages 18-70
  • All Genders

Study Summary

ivermectin is FDA approaved antiparasitic drug which is also claimed to be having potent in vitro antiviral effect,so we are tryying to study itsovid19 anosmia effect upon releiving post covid19 anosmia

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • post covid19 anosmia
  • negative swab test for covid19

Exclusion

Exclusion Criteria:

  • other types of anosmia ,
  • no local or central other causes of anosmia
  • still active covid 19 pateints ( positive swab test )

Study Design

Total Participants: 117
Study Start date:
April 20, 2021
Estimated Completion Date:
May 15, 2022

Study Description

ivermectin is FDA approaved antiparasitic drug which is also claimed to be having potent in vitro antiviral effect,so we are tryying to study itsovid19 anosmia effect upon releiving post covid19 anosmia as one of the most characteresic symptoms of covid19 infection

Connect with a study center

  • Zaky Aref

    Qina,
    Egypt

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.